Suppr超能文献

[乳腺癌女性的新辅助抗激素治疗]

[Neoadjuvant antihormonal treatment of women with breast cancer].

作者信息

Tuxen Malgorzata K, Kamby Claus, Nielsen Dorte Lisbet

机构信息

Herlev Hospital, Onkologisk Afdeling R, Herlev.

出版信息

Ugeskr Laeger. 2007 Sep 10;169(37):3077-81.

Abstract

The main goal of neoadjuvant treatment for large operable or locally-advanced breast cancer is downstaging tumors. It may allow breast-conserving surgery on tumors that are unsuitable at initial presentation or convert some inoperable breast cancers into tumors that are operable. Neoadjuvant antihormonal therapy for receptor positive tumors is an effective and safe alternative to chemotherapy in elderly postmenopausal women. This paper presents an updated overview of the results from early phase II studies of neoadjuvant endocrine therapy, randomized trials of tamoxifen as primary treatment versus primary operation, and randomized phase III trials which compare tamoxifen and aromatase inhibitors.

摘要

对于可手术切除的大型或局部晚期乳腺癌,新辅助治疗的主要目标是降低肿瘤分期。它可能使最初不适合保乳手术的肿瘤能够进行保乳手术,或者将一些无法手术切除的乳腺癌转变为可手术切除的肿瘤。对于受体阳性肿瘤,新辅助抗激素治疗对于老年绝经后女性而言是一种有效且安全的化疗替代方案。本文提供了新辅助内分泌治疗早期II期研究、他莫昔芬作为主要治疗与初次手术对比的随机试验以及比较他莫昔芬和芳香化酶抑制剂的随机III期试验结果的最新综述。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验